Patent intelligence · US
US 11471517
Compositions and methods for preventing and treating graft versus host disease
Compositions and methods for preventing and treating graft versus host disease
Patent details — US 11471517
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 18, 2022
- Expiration
- Oct 13, 2042
- Applicant
- Regents of the University of Minnesota
- Claims
- 8
- CPC classes
- A61K, A61K2035/122, A61K2035/124, A61K2039/5154
Quick answer
US 11471517 (Compositions and methods for preventing and treating graft versus host disease) is held by Regents of the University of Minnesota. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regents of the University of Minnesota
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K2035/122, A61K2035/124, A61K2039/5154, A61K2039/577, A61K35/17
More from Regents of the University of Minnesota
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11471517?
US 11471517 (Compositions and methods for preventing and treating graft versus host disease) is held by Regents of the University of Minnesota. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11471517?
Regents of the University of Minnesota is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11471517 expire?
Our index shows an expiration date of Oct 13, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.